Compare Boston Scientific Corporation (BSX) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Alphabet Inc Class A — how do they compare? Boston Scientific Corporation trades at $43.33 (market cap $66.37B), while Alphabet Inc Class A trades at $367.31 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 65.8× Boston Scientific Corporation's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | GOOGL | |
|---|---|---|
Market Cap | $66.37B | $4.37T |
Sector | Health | Media |
52-Week High | $108.14 | $402.62 |
52-Week Low | $42.63 | $182.00 |
Enterprise Value | $75.94B | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Alphabet (GOOGL) trades at $367.14, up 4.15% today, with a neutral technical signal and strong fundamentals. The stock shows robust profitability with a 37.92% net margin and consistent earnings beats, including Q1 2026 EPS of $5.11 versus $2.64 expected. Revenue grew to $402.84B in 2025, and operating cash flow surged to $164.71B. Analysts are overwhelmingly bullish with an 85.19% buy rating and a $431.78 consensus price target. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube subscription price increases.
The outlook for GOOGL remains positive, supported by AI expansion and solid financials, but risks include antitrust scrutiny and market volatility. The stock offers upside to analyst targets, though investors should monitor competitive pressures and regulatory developments that could impact growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
